急性期ケアシンドロミック検査市場 - 世界の産業規模、シェア、動向、機会、予測：疾患別、対象別、サンプルの種類別、エンドユーザー別、地域別、競合別、2020年～2030年

急性期ケアシンドロミック検査の世界市場規模は2024年に31億2,000万米ドルで、予測期間には46億7,000万米ドルに達し、2030年までのCAGRは6.91%になると予測されています。

急性期ケアシンドロミック検査市場とは、ヘルスケア環境、特に救急部や急性期ケア施設において、患者の急性症状や状態の原因を迅速に特定・診断するために使用される診断アプローチです。このアプローチでは、患者の症状の原因となりうる複数の病原体（ウイルス、細菌、その他の微生物など）を同時に検査します。その目的は、潜在的な原因を迅速に絞り込み、適切な治療方針を決定することです。急性期ケアシンドロミック検査は、患者が様々な感染因子に起因する可能性のある症状を呈している状況で特に重要です。この検査戦略により、ヘルスケア提供者は患者のケア、隔離措置、治療オプションに関して、タイムリーで十分な情報に基づいた決定を下すことができます。この検査は、疾患の流行やパンデミックの際に特に有用であり、ヘルスケアシステムが同様の症状を持つ多数の患者を効率的に管理し、対応するのに役立つからです。しかし、急性期ケアシンドロミック検査で使用される検査の具体的な種類には、分子アッセイ（ポリメラーゼ連鎖反応やPCR検査など）、迅速抗原検査、血清学的検査（抗体を調べる）、その他の診断法が含まれます。検査の選択は、疑われる病原体や臨床状況によって異なります。

市場促進要因

感染症アウトブレイクの増加

主な市場課題

他の診断検査との競合

主な市場動向

ポイントオブケア検査（POCT）の台頭

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の急性期ケアシンドロミック検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患別（呼吸器疾患、消化器疾患、泌尿生殖器疾患、熱帯病、その他）
  • 対象別（細菌、ウイルス、真菌、寄生虫）
  • サンプルの種類別（血液、尿、体液、便、綿棒、その他）
  • エンドユーザー別（病院、臨床・診断研究所、調査・学術機関、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の急性期ケアシンドロミック検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の急性期ケアシンドロミック検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の急性期ケアシンドロミック検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の急性期ケアシンドロミック検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの急性期ケアシンドロミック検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Abbott Laboratories
• Becton, Dickinson and Company
• Biocartis NV
• bioMerieux SA（BioFire Diagnostics）
• Danaher Corporation（Cepheid, Inc.）
• DiaSorin S.p.A（Luminex Corporation）
• Eurofins Scientific（Eurofins Viracor）
• Hologic Inc.
• Laboratory Corporation of America Holdings.
• QIAGEN N.V.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Acute Care Syndromic Testing Market was valued at USD 3.12 billion in 2024 and is expected to reach USD 4.67 billion in the forecast period with a CAGR of 6.91% through 2030. Acute Care Syndromic Testing Markets are diagnostic approach used in healthcare settings, particularly in emergency departments and acute care facilities, to rapidly identify and diagnose the cause of acute symptoms or conditions in patients. This approach involves the simultaneous testing of multiple pathogens (such as viruses, bacteria, and other microorganisms) that could be responsible for a patient's symptoms. The goal is to quickly narrow down the potential causes and guide appropriate treatment decisions. Acute care syndromic testing is especially important in situations where patients present with symptoms that could be attributed to various infectious agents. This testing strategy allows healthcare providers to make timely and informed decisions regarding patient care, isolation measures, and treatment options. It can be particularly valuable during disease outbreaks or pandemics, as it helps healthcare systems efficiently manage and respond to a large number of patients with similar symptoms. However, The specific types of tests used in acute care syndromic testing may include molecular assays (like polymerase chain reaction or PCR tests), rapid antigen tests, serological tests (looking for antibodies), and other diagnostic methods. The choice of tests depends on the suspected pathogens and the clinical context.

Key Market Drivers

Rise in Infectious Disease Outbreaks

The rise in infectious disease outbreaks has a significant impact on driving the growth of the global acute care syndromic testing market. Infectious disease outbreaks create a heightened demand for rapid and accurate diagnostic solutions, and acute care syndromic testing addresses this need. Influenza is the most common infectious disease in the world, but some diseases are more prevalent than others. In the United States alone, about 1 in every 5 people gets the flu every year, but only about 300 people get prion disease each year. Acute care syndromic testing enables healthcare providers to quickly identify the pathogens responsible for the outbreak. Rapid diagnosis allows for early detection and timely implementation of containment measures, such as isolating infected individuals and implementing infection control protocols. During an outbreak, healthcare facilities experience an influx of patients with similar symptoms. Acute care syndromic testing streamlines patient management by providing a comprehensive assessment of the potential pathogens causing the outbreak, allowing for appropriate treatment and care planning. Identifying the causative agent of an outbreak promptly helps limit its spread within the community and healthcare settings. Acute care syndromic testing assists in identifying carriers, isolating cases, and preventing further transmission. Different infectious agents may require specific treatments. Acute care syndromic testing aids in tailoring treatment plans by providing information about the pathogens involved and their susceptibility to different therapies, which can lead to more effective patient outcomes. Outbreaks often strain healthcare resources. Acute care syndromic testing optimizes resource allocation by quickly identifying cases that require immediate attention and enabling efficient use of medical supplies, personnel, and facilities. Infectious disease outbreaks have highlighted the importance of global health security. Acute care syndromic testing is a critical tool in enhancing preparedness and response capabilities, ensuring a rapid and effective response to emerging threats.

The increasing frequency of global outbreaks such as COVID-19, Zika, Ebola, and emerging influenza strains has underscored the urgent need for robust syndromic testing platforms that can detect a wide array of pathogens within hours. This rapid detection is critical not only for individual patient care but also for public health surveillance, enabling governments and health agencies to monitor the spread of infectious diseases in real time. Acute care syndromic testing systems integrate automation, multiplexing, and high-throughput capabilities, allowing labs and emergency departments to manage high patient volumes while ensuring diagnostic accuracy. These innovations have made syndromic testing essential during crisis scenarios where timely responses can mitigate large-scale outbreaks.

According to the World Health Organization (WHO), infectious diseases cause over 17 million deaths annually, with respiratory infections alone accounting for around 4 million of these cases. This staggering burden emphasizes the need for faster diagnostic interventions in acute settings. The global interconnectedness of travel and trade has increased the speed at which pathogens can cross borders, making syndromic testing a critical first line of defense in hospitals and clinics worldwide. As healthcare systems continue to evolve to handle pandemics and antibiotic resistance, the integration of acute care syndromic testing into emergency protocols is likely to become standard practice, driving sustained growth in the market.

Key Market Challenges

Competition from other diagnostic tests

Syndromic testing competes with other diagnostic tests, such as molecular diagnostics and serological diagnostics. These tests may be more accurate and can provide more information about the underlying cause of the syndrome. molecular diagnostics can identify the specific pathogen causing the syndrome, while serological diagnostics can detect the presence of antibodies to the pathogen. This information can be helpful in making a diagnosis and determining the best course of treatment. Healthcare providers may be more accustomed to using traditional diagnostic methods that they are already familiar with, which can lead to a resistance to adopting newer syndromic testing approaches. Diagnostic methods that have a long history of use and established reliability may be favored by healthcare professionals, making it difficult for syndromic testing to gain traction.

Key Market Trends

Rise of Point-of-Care-Testing (POCT)

The rise of Point-of-Care Testing (POCT) is a significant trend in the global Acute Care Syndromic Testing Market. Point-of-Care Testing refers to diagnostic testing performed at or near the patient's location, providing rapid results that can guide immediate clinical decision-making. POCT allows healthcare providers to quickly diagnose and initiate treatment plans, particularly in acute care settings where time is critical. Acute care syndromic testing, when adapted to POCT platforms, enables rapid identification of pathogens responsible for acute symptoms, leading to more timely and appropriate interventions. Syndromic testing conducted at the point of care eliminates the need to send samples to centralized laboratories, reducing turnaround times for results. This speed is essential in managing acute conditions and outbreaks, where rapid decisions are crucial. Point-of-care syndromic testing empowers healthcare providers to make informed decisions at the bedside. Immediate results help guide isolation measures, treatment choices, and patient management strategies, improving overall care. In situations such as infectious disease outbreaks, POCT-based acute care syndromic testing can contribute to rapid containment by quickly identifying cases and implementing appropriate control measures to prevent further spread. POCT helps optimize resource allocation by avoiding unnecessary transfers, repeat tests, and prolonged hospital stays. This efficiency is especially relevant in acute care scenarios where resources may be limited. During events like large gatherings or disaster response, point-of-care syndromic testing can provide rapid screening for infectious diseases, aiding in quick identification and management of potential outbreaks. POCT can be particularly valuable in remote or underserved regions with limited access to central laboratories. Acute care syndromic testing at the point of care bridges the gap in diagnostic capabilities. Real-time Surveillance: Point-of-care syndromic testing generates data that can be analyzed in real time, contributing to disease surveillance efforts, early detection of emerging pathogens, and timely public health responses.

Key Market Players

Abbott Laboratories

Becton, Dickinson and Company

Biocartis NV

bioMerieux SA (BioFire Diagnostics)

Danaher Corporation (Cepheid, Inc.)

DiaSorin S.p.A (Luminex Corporation)

Eurofins Scientific (Eurofins Viracor)

Hologic Inc.

Laboratory Corporation of America Holdings.

QIAGEN N.V.

Report Scope:

In this report, the Global Acute Care Syndromic Testing Markets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Care Syndromic Testing Market, By Disease Type:

• Respiratory Diseases
• Gastrointestinal Diseases
• Genitourinary Diseases
• Tropical Diseases
• Others

Acute Care Syndromic Testing Market, By Target:

• Bacteria
• Fungi
• Viruses
• Parasites

Acute Care Syndromic Testing Market, By Sample Type:

• Blood
• Urine
• Biofluids
• Stool
• Swabs
• Others

Acute Care Syndromic Testing Market, By End User:

• Hospitals
• Clinical & Diagnostics Laboratories
• Research & Academic Institutions
• Others

Acute Care Syndromic Testing Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Major companies present in the Global Acute Care Syndromic Testing Market.

Available Customizations:

Global Acute Care Syndromic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Care Syndromic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Others)
  • 5.2.2. By Target (Bacteria, Viruses, Fungi, Parasites)
  • 5.2.3. By Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others)
  • 5.2.4. By End User (Hospitals, Clinical & Diagnostics Laboratories, Research & Academic Institutions, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Acute Care Syndromic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Target
  • 6.2.3. By Sample Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acute Care Syndromic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Target
      • 6.3.1.2.3. By Sample Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Acute Care Syndromic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Target
      • 6.3.2.2.3. By Sample Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Acute Care Syndromic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Target
      • 6.3.3.2.3. By Sample Type
      • 6.3.3.2.4. By End User

7. Europe Acute Care Syndromic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Target
  • 7.2.3. By Sample Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Acute Care Syndromic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Target
      • 7.3.1.2.3. By Sample Type
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Acute Care Syndromic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Target
      • 7.3.2.2.3. By Sample Type
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Acute Care Syndromic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Target
      • 7.3.3.2.3. By Sample Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Acute Care Syndromic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Target
      • 7.3.4.2.3. By Sample Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Acute Care Syndromic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Target
      • 7.3.5.2.3. By Sample Type
      • 7.3.5.2.4. By End User

8. Asia-Pacific Acute Care Syndromic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Target
  • 8.2.3. By Sample Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Acute Care Syndromic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Target
      • 8.3.1.2.3. By Sample Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Acute Care Syndromic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Target
      • 8.3.2.2.3. By Sample Type
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Acute Care Syndromic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Target
      • 8.3.3.2.3. By Sample Type
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Acute Care Syndromic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Target
      • 8.3.4.2.3. By Sample Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Acute Care Syndromic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Target
      • 8.3.5.2.3. By Sample Type
      • 8.3.5.2.4. By End User

9. South America Acute Care Syndromic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Target
  • 9.2.3. By Sample Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Acute Care Syndromic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Target
      • 9.3.1.2.3. By Sample Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Acute Care Syndromic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Target
      • 9.3.2.2.3. By Sample Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Acute Care Syndromic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Target
      • 9.3.3.2.3. By Sample Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa Acute Care Syndromic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Target
  • 10.2.3. By Sample Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Acute Care Syndromic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Target
      • 10.3.1.2.3. By Sample Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Acute Care Syndromic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Target
      • 10.3.2.2.3. By Sample Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Acute Care Syndromic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Target
      • 10.3.3.2.3. By Sample Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Abbott Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Becton, Dickinson and Company
• 15.3. Biocartis NV
• 15.4. bioMerieux SA (BioFire Diagnostics)
• 15.5. Danaher Corporation (Cepheid, Inc.)
• 15.6. DiaSorin S.p.A (Luminex Corporation)
• 15.7. Eurofins Scientific (Eurofins Viracor)
• 15.8. Hologic Inc.
• 15.9. Laboratory Corporation of America Holdings.
• 15.10. QIAGEN N.V.

16. Strategic Recommendations

17. About Us & Disclaimer